Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.American College of Rheumatology (ACR) developed hybrid score, a new measure of response to rheumatoid arthritis (RA) treatment, has showed improved sensitivity compared to traditional ACR20/50/70 and DAS28 scores in a post-hoc analysis of the RAPID 1 (Rheumatoid Arthritis PreventIon of structural Damage) study.
Subscribe to our email newsletter
The ACR hybrid score combines conventional ACR20/50/70 scores with the mean percent change in all 7 ACR core components, providing a percent improvement from baseline on a continuous scale.
RAPID 1 is a phase III double-blind placebo-controlled trial intended to determine the efficacy and tolerability of certolizumab pegol together with methotrexate (MTX), to treat active RA in patients who did not adequately respond to conventional treatment.
In the study, the ACR hybrid was combined with the conventional ACR20/50/70 scores with the mean percent change in all 7 ACR core components, providing a percent improvement from baseline on a continuous scale.
The results from this post hoc analysis suggest that certolizumab pegol plus MTX conferred greater benefit than placebo plus MTX regardless of measures according to ACR20 responder rates, ACR hybrid scores and mean changes from baseline in the DAS28.